Earlier diagnosis and advances in treatment have reduced cancer patients’ mortality over the past decade in the mature markets. Developing markets will continue to see benefits in cancer survival. Cancer patients’ risk of recurrence has also declined dramatically. These advances will cause the coming decade to see growth in the number of people living with cancer outpace growth in the number of cases diagnosed annually in many markets.

Questions Answered in This Report:

  • What are the global trends in incident and prevalent populations in CML and prostate cancer through 2024? Changes in risk or survival are a key contributor to CML prevalent populations in developing markets, whereas changes in population aging and population growth is a strong influence on CML and CaP prevalent populations in mature markets.

  • To what extent will increased survival in CML change the populations eligible for therapy? Patient access to targeted therapy will increase in the coming decade, and increases in access will be most dramatic in cost-constrained markets as low-cost generic competitors to Novartis’s Gleevec (imatinib) are launched. Increased survival in CML will drive growth of the population eligible for chronic therapy across all markets.

  • How will advances in diagnosis and treatment of CaP affect growth in the treatable populations through 2024? Earlier detection, improved therapy, and improved access to therapy for CaP will fuel growth in the treatable populations. The adjuvant drug-treatable population in developing countries will see growth as access to advanced treatment expands. As CaP patients benefit from access to adjuvant treatment, the cases that survive and are eligible for chronic therapy (adjuvant prevalent population) will also see growth. Improvements in treatment of advanced stage CaP will also swell the advanced prevalent population.


Markets covered: Europe; Middle East & Africa; North America; South America; East Asia &Pacific.

Epidemiology: Country-specific growth rates in diagnosed incident cases of CML and CaP in select markets, 2014-2024; Country-specific growth rates in prevalent populations of CML and CaP in select markets, 2014-2024; Growth of CaP adjuvant treatable populations in select markets, 2014-2024; Growth of CaP adjuvant prevalent populations in key markets, 2014-2024; Growth of the advanced prevalent population of CaP in the mature markets, 2014-2024.

Author(s): Michael Hughes, M.Sc., Ph.D.

Related Reports

Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

View Details

Prostate Cancer - Epidemiology - Mature Markets Data

DRG Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We repor...

View Details

Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Hormone Sensititve

The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval...

View Details